Does the Identification of a Minimum Number of Cases Correlate With Better Adherence to International Guidelines Regarding the Treatment of Penile Cancer? Survey Results of the European PROspective Penile Cancer Study (E-PROPS)

Standard

Does the Identification of a Minimum Number of Cases Correlate With Better Adherence to International Guidelines Regarding the Treatment of Penile Cancer? Survey Results of the European PROspective Penile Cancer Study (E-PROPS). / Lebentrau, Steffen; Wakileh, Gamal Anton; Schostak, Martin; Schmid, Hans-Peter; Suarez-Ibarrola, Rodrigo; Merseburger, Axel S; Hutterer, Georg C; Necknig, Ulrike H; Rink, Michael; Bögemann, Martin; Kluth, Luis Alex; Pycha, Armin; Burger, Maximilian; Brookman-May, Sabine D; Bründl, Johannes; May, Matthias.

In: FRONT ONCOL, Vol. 11, 759362, 2021.

Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

Harvard

Lebentrau, S, Wakileh, GA, Schostak, M, Schmid, H-P, Suarez-Ibarrola, R, Merseburger, AS, Hutterer, GC, Necknig, UH, Rink, M, Bögemann, M, Kluth, LA, Pycha, A, Burger, M, Brookman-May, SD, Bründl, J & May, M 2021, 'Does the Identification of a Minimum Number of Cases Correlate With Better Adherence to International Guidelines Regarding the Treatment of Penile Cancer? Survey Results of the European PROspective Penile Cancer Study (E-PROPS)', FRONT ONCOL, vol. 11, 759362. https://doi.org/10.3389/fonc.2021.759362

APA

Lebentrau, S., Wakileh, G. A., Schostak, M., Schmid, H-P., Suarez-Ibarrola, R., Merseburger, A. S., Hutterer, G. C., Necknig, U. H., Rink, M., Bögemann, M., Kluth, L. A., Pycha, A., Burger, M., Brookman-May, S. D., Bründl, J., & May, M. (2021). Does the Identification of a Minimum Number of Cases Correlate With Better Adherence to International Guidelines Regarding the Treatment of Penile Cancer? Survey Results of the European PROspective Penile Cancer Study (E-PROPS). FRONT ONCOL, 11, [759362]. https://doi.org/10.3389/fonc.2021.759362

Vancouver

Bibtex

@article{e34c62cd8c1c40efa3691f957d23fc5b,
title = "Does the Identification of a Minimum Number of Cases Correlate With Better Adherence to International Guidelines Regarding the Treatment of Penile Cancer? Survey Results of the European PROspective Penile Cancer Study (E-PROPS)",
abstract = "Background: Penile cancer represents a rare malignant disease, whereby a small caseload is associated with the risk of inadequate treatment expertise. Thus, we hypothesized that strict guideline adherence might be considered a potential surrogate for treatment quality. This study investigated the influence of the annual hospital caseload on guideline adherence regarding treatment recommendations for penile cancer.Methods: In a 2018 survey study, 681 urologists from 45 hospitals in four European countries were queried about six hypothetical case scenarios (CS): local treatment of the primary tumor pTis (CS1) and pT1b (CS2); lymph node surgery inguinal (CS3) and pelvic (CS4); and chemotherapy neoadjuvant (CS5) and adjuvant (CS6). Only the responses from 206 head and senior physicians, as decision makers, were evaluated. The answers were assessed based on the applicable European Association of Urology (EAU) guidelines regarding their correctness. The real hospital caseload was analyzed based on multivariate logistic regression models regarding its effect on guideline adherence.Results: The median annual hospital caseload was 6 (interquartile range (IQR) 3-9). Recommendations for CS1-6 were correct in 79%, 66%, 39%, 27%, 28%, and 28%, respectively. The probability of a guideline-adherent recommendation increased with each patient treated per year in a clinic for CS1, CS2, CS3, and CS6 by 16%, 7.8%, 7.2%, and 9.5%, respectively (each p < 0.05); CS4 and CS5 were not influenced by caseload. A caseload threshold with a higher guideline adherence for all endpoints could not be perceived. The type of hospital care (academic vs. non-academic) did not affect guideline adherence in any scenario.Conclusions: Guideline adherence for most treatment recommendations increases with growing annual penile cancer caseload. Thus, the results of our study call for a stronger centralization of diagnosis and treatment strategies regarding penile cancer.",
author = "Steffen Lebentrau and Wakileh, {Gamal Anton} and Martin Schostak and Hans-Peter Schmid and Rodrigo Suarez-Ibarrola and Merseburger, {Axel S} and Hutterer, {Georg C} and Necknig, {Ulrike H} and Michael Rink and Martin B{\"o}gemann and Kluth, {Luis Alex} and Armin Pycha and Maximilian Burger and Brookman-May, {Sabine D} and Johannes Br{\"u}ndl and Matthias May",
note = "Copyright {\textcopyright} 2021 Lebentrau, Wakileh, Schostak, Schmid, Suarez-Ibarrola, Merseburger, Hutterer, Necknig, Rink, B{\"o}gemann, Kluth, Pycha, Burger, Brookman-May, Br{\"u}ndl and May.",
year = "2021",
doi = "10.3389/fonc.2021.759362",
language = "English",
volume = "11",
journal = "FRONT ONCOL",
issn = "2234-943X",
publisher = "Frontiers Media S. A.",

}

RIS

TY - JOUR

T1 - Does the Identification of a Minimum Number of Cases Correlate With Better Adherence to International Guidelines Regarding the Treatment of Penile Cancer? Survey Results of the European PROspective Penile Cancer Study (E-PROPS)

AU - Lebentrau, Steffen

AU - Wakileh, Gamal Anton

AU - Schostak, Martin

AU - Schmid, Hans-Peter

AU - Suarez-Ibarrola, Rodrigo

AU - Merseburger, Axel S

AU - Hutterer, Georg C

AU - Necknig, Ulrike H

AU - Rink, Michael

AU - Bögemann, Martin

AU - Kluth, Luis Alex

AU - Pycha, Armin

AU - Burger, Maximilian

AU - Brookman-May, Sabine D

AU - Bründl, Johannes

AU - May, Matthias

N1 - Copyright © 2021 Lebentrau, Wakileh, Schostak, Schmid, Suarez-Ibarrola, Merseburger, Hutterer, Necknig, Rink, Bögemann, Kluth, Pycha, Burger, Brookman-May, Bründl and May.

PY - 2021

Y1 - 2021

N2 - Background: Penile cancer represents a rare malignant disease, whereby a small caseload is associated with the risk of inadequate treatment expertise. Thus, we hypothesized that strict guideline adherence might be considered a potential surrogate for treatment quality. This study investigated the influence of the annual hospital caseload on guideline adherence regarding treatment recommendations for penile cancer.Methods: In a 2018 survey study, 681 urologists from 45 hospitals in four European countries were queried about six hypothetical case scenarios (CS): local treatment of the primary tumor pTis (CS1) and pT1b (CS2); lymph node surgery inguinal (CS3) and pelvic (CS4); and chemotherapy neoadjuvant (CS5) and adjuvant (CS6). Only the responses from 206 head and senior physicians, as decision makers, were evaluated. The answers were assessed based on the applicable European Association of Urology (EAU) guidelines regarding their correctness. The real hospital caseload was analyzed based on multivariate logistic regression models regarding its effect on guideline adherence.Results: The median annual hospital caseload was 6 (interquartile range (IQR) 3-9). Recommendations for CS1-6 were correct in 79%, 66%, 39%, 27%, 28%, and 28%, respectively. The probability of a guideline-adherent recommendation increased with each patient treated per year in a clinic for CS1, CS2, CS3, and CS6 by 16%, 7.8%, 7.2%, and 9.5%, respectively (each p < 0.05); CS4 and CS5 were not influenced by caseload. A caseload threshold with a higher guideline adherence for all endpoints could not be perceived. The type of hospital care (academic vs. non-academic) did not affect guideline adherence in any scenario.Conclusions: Guideline adherence for most treatment recommendations increases with growing annual penile cancer caseload. Thus, the results of our study call for a stronger centralization of diagnosis and treatment strategies regarding penile cancer.

AB - Background: Penile cancer represents a rare malignant disease, whereby a small caseload is associated with the risk of inadequate treatment expertise. Thus, we hypothesized that strict guideline adherence might be considered a potential surrogate for treatment quality. This study investigated the influence of the annual hospital caseload on guideline adherence regarding treatment recommendations for penile cancer.Methods: In a 2018 survey study, 681 urologists from 45 hospitals in four European countries were queried about six hypothetical case scenarios (CS): local treatment of the primary tumor pTis (CS1) and pT1b (CS2); lymph node surgery inguinal (CS3) and pelvic (CS4); and chemotherapy neoadjuvant (CS5) and adjuvant (CS6). Only the responses from 206 head and senior physicians, as decision makers, were evaluated. The answers were assessed based on the applicable European Association of Urology (EAU) guidelines regarding their correctness. The real hospital caseload was analyzed based on multivariate logistic regression models regarding its effect on guideline adherence.Results: The median annual hospital caseload was 6 (interquartile range (IQR) 3-9). Recommendations for CS1-6 were correct in 79%, 66%, 39%, 27%, 28%, and 28%, respectively. The probability of a guideline-adherent recommendation increased with each patient treated per year in a clinic for CS1, CS2, CS3, and CS6 by 16%, 7.8%, 7.2%, and 9.5%, respectively (each p < 0.05); CS4 and CS5 were not influenced by caseload. A caseload threshold with a higher guideline adherence for all endpoints could not be perceived. The type of hospital care (academic vs. non-academic) did not affect guideline adherence in any scenario.Conclusions: Guideline adherence for most treatment recommendations increases with growing annual penile cancer caseload. Thus, the results of our study call for a stronger centralization of diagnosis and treatment strategies regarding penile cancer.

U2 - 10.3389/fonc.2021.759362

DO - 10.3389/fonc.2021.759362

M3 - SCORING: Journal article

C2 - 34912711

VL - 11

JO - FRONT ONCOL

JF - FRONT ONCOL

SN - 2234-943X

M1 - 759362

ER -